Search Results
Aug 06, 2026, 16:05 ET Artivion Reports Second Quarter 2026 Financial Results
Ltd.ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.
More news about: Artivion, Inc.
Jul 28, 2026, 16:10 ET Artivion to Participate in Upcoming Investor Conferences
ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.
More news about: Artivion, Inc.
Jul 23, 2026, 16:10 ET Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released
More news about: Artivion, Inc.
Jun 29, 2026, 07:00 ET Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the
More news about: Artivion, Inc.
Jun 10, 2026, 16:10 ET Artivion to Participate in the 2026 Truist Securities MedTech Conference
ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 Truist Securities
More news about: Artivion, Inc.
May 18, 2026, 07:00 ET Artivion Completes Acquisition of Endospan Ltd.
ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"),
More news about: Artivion, Inc.
May 11, 2026, 11:30 ET Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.
May 11, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Artivion (NYSE: AORT). The investigation results from inaccurate statements Artivion may have made regarding its financial statements, business operations and prospects.
More news about: Ademi LLP
May 07, 2026, 16:05 ET Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
loansATLANTA, May 7, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31,
More news about: Artivion, Inc.
Apr 23, 2026, 16:15 ET Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
ATLANTA, April 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2026 financial results will be released
More news about: Artivion, Inc.
Apr 07, 2026, 07:00 ET Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System
dissectionsATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved
More news about: Artivion, Inc.
Mar 03, 2026, 16:10 ET Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
ATLANTA, March 3, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate virtually at the upcoming Oppenheimer
More news about: Artivion, Inc.
Feb 12, 2026, 16:05 ET Artivion Reports Fourth Quarter and Full Year 2025 Financial Results
measures.ATLANTA, Feb. 12, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the fourth quarter and year ended December
More news about: Artivion, Inc.
Feb 02, 2026, 08:00 ET Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting
AMDSATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS
More news about: Artivion, Inc.
Jan 29, 2026, 16:05 ET Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results
ATLANTA, Jan. 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial results will be released
More news about: Artivion, Inc.
Nov 06, 2025, 16:05 ET Artivion Reports Third Quarter 2025 Financial Results
ATLANTA, Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September
More news about: Artivion, Inc.
Nov 06, 2025, 08:00 ET Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
ATLANTA, Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal
More news about: Artivion, Inc.
Oct 29, 2025, 16:10 ET Artivion to Participate in the Stifel 2025 Healthcare Conference
ATLANTA, Oct. 29, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming Stifel 2025 Healthcare
More news about: Artivion, Inc.
Oct 23, 2025, 16:10 ET Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results
ATLANTA, Oct. 23, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial results will be released
More news about: Artivion, Inc.
Oct 13, 2025, 08:00 ET Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
ATLANTA, Oct. 13, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS PERSEVERE and PROTECT trials were presented
More news about: Artivion, Inc.